Fintech PR
Ferrero Group reports Consolidated Financial Statements for the 2022/2023 Financial Year
- The Ferrero Group continues its growth trajectory with a 21% increase in turnover to EUR17 billion and a 14% rise in its global workforce to 47,212 employees.
- The Group expanded its presence in North America with the strategic acquisition of ice cream maker Wells Enterprises Inc.
LUXEMBOURG, Feb. 14, 2024 /PRNewswire/ — The Ferrero Group, through its holding company Ferrero International S.A., approved the Consolidated Financial Statements for the 2022/2023 financial year, which ended on August 31, 20231. The Group closed the financial year with a consolidated turnover of EUR17 billion, an increase of +20.7% compared to the previous year’s turnover of EUR14 billion, boosted by both organic growth and acquisitions, continuing the growth strategy driven by the Executive Chairman Giovanni Ferrero and executed by CEO Lapo Civiletti.
Despite a 2022/2023 financial year marked by a challenging economic and geopolitical environment, the Ferrero Group was able to continue its robust growth and consolidate its market share across categories and regions thanks to the resilience of its people, brands, and business model. Ferrero’s manufacturing plants worldwide grew to 37 from 32 the previous year, while the Group’s global workforce as of August 31, 2023 amounted to 47,212 employees, up from 41,441 as of August 31, 2022.
“We are pleased to report a period of strong growth despite the economic and geopolitical challenges, with continued inflationary pressures remaining a factor across the globe. In addition to revenue growth, the global workforce has also grown by over 5,000 people, which is a testament of the long- term vision of our business strategy,” said Daniel Martinez Carretero, Chief Financial Officer at Ferrero Group.
At the end of January 2023, the Group completed the acquisition of Wells Enterprises Inc., its operations, and its strong portfolio of iconic brands, which include Blue Bunny®, Blue Ribbon Classics®, Bomb Pop® and Halo Top®. The acquisition is part of the Ferrero Group’s strategic growth ambition to expand its business in North America and in the ice cream category. The deal also included four US manufacturing facilities, located in the states of Iowa, Nevada, and New York.
At the end of March 2023, the Group also finalized the acquisition of Fresystem Group, an Italian family-owned business that produces frozen bakery products. The acquisition is part of Ferrero’s strategic growth plans and follows the launch of Nutella Muffins, which have been produced by Fresystem since 2021.
Innovation remains at the core of our DNA to support the growth of Ferrero’s most iconic brands, expanding their presence into new categories of the Sweet Packaged Food arena, thus meeting new consumer needs. This was exemplified in the 22/23 fiscal year by the introduction of new Kinder, Rocher, and Raffaello references within the Ice Cream segment across Europe, and the successful roll out of Nutella Biscuits and Nutella B-ready in the United States.
The Group has expanded its production capacity to meet increasing demand for Ferrero’s products. This financial period saw total capital investments of EUR 811 million – the main investments were property, plant and equipment in Italy, the United States, Germany, and Spain.
With the Group’s long-term approach to growth under the leadership of Executive Chairman Giovanni Ferrero, comes an always-on attention to sustainability. The Group sustainability strategy is focused on four key pillars: protecting the environment, sustainably sourcing high-quality ingredients, promoting responsible consumption, and empowering people.
Ferrero Group
Ferrero began its journey as a pastry shop in the small town of Alba in Piedmont, Italy, in 1946. Today, it is one of the world’s largest sweet-packaged food companies, with much loved brands sold in more than 170 countries. The Ferrero Group brings joy to people around the world with much-loved products including Nutella®, Kinder®, Tic Tac®, and Ferrero Rocher®.
About 47,000 employees are passionate about helping people celebrate life’s special moments. The Ferrero Group’s family culture, now in its third generation, is based on dedication to quality and excellence, heritage and a commitment to the planet and communities in which we operate.
For more information, please visit www.Ferrero.com
Contact: [email protected]
1 From 1 September 2022 to 31 August 2023
View original content:https://www.prnewswire.com/news-releases/ferrero-group-reports-consolidated-financial-statements-for-the-20222023-financial-year-302061637.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Clayfin Technologies and Jana Small Finance Bank Honored with Prestigious IBSi Digital Banking Award 2024
-
Latest News4 days ago
HANDSHAKE SPEAKEASY IN MEXICO CITY NAMED AS THE BEST BAR IN NORTH AMERICA AS RANKING OF NORTH AMERICA’S 50 BEST BARS IS REVEALED AT THIRD ANNUAL AWARDS CEREMONY
-
Latest News3 days ago
Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade
-
Latest News6 days ago
Colombia to showcase sustainable investment opportunities at the Investment Roadshow in London
-
Latest News6 days ago
Nium Expands Regional Footprint in Asia; Signs Partnership MOU with Indonesian Payments Infrastructure Leader, Artajasa
-
Latest News4 days ago
SDAX Unveils World’s First Securitised Gold Tokens for Digital Exchange Users
-
Latest News4 days ago
BINGHATTI LAUNCHES ITS DEBUT PROJECT ADJACENT TO DUBAI HILLS
-
Latest News6 days ago
Basware Helps Companies Prevent $1m in Losses for every $1bn Spent